Seeking Alpha

FOHC Resources

 
View as an RSS Feed
View FOHC Resources' Comments BY TICKER:
Latest  |  Highest rated
  • Why Isn't Yahoo Worth Significantly More? [View article]
    Nice article. One thing I would add that helps put things in perspective in terms of Yahoo's value...the average price to book ratio for internet stocks is 5, even unprofitable tech stocks often trade at above 3. Yahoo is currently at about 1. So even if they were to only trade at 2, it would still equate to an $80 stock price assuming Baba shares are relatively stable. http://bit.lyw4jRpw~ADAMODAR/New_Ho...
    Sep 23 06:23 PM | 3 Likes Like |Link to Comment
  • Amazingly, Yahoo Will Still Do Badly [View article]
    According to Yahoo's balance sheet they have about 16B in assets, but it is plainly evident that their remaining stake in Alibaba alone is worth more than that. Even if you grossly overestimate the taxes Yahoo could pay on the Alibaba stake, Yahoo is still trading at less that 2x book value at $40. Considering that it is almost unheard of for a profitable tech company to trade at a price to book ratio that low, Yahoo isn't expensive, it's a value proposition.
    Sep 19 01:43 PM | Likes Like |Link to Comment
  • Boy, Were We Wrong About Yahoo [View article]
    It seems like there is a nearly ubiquitous misunderstanding of valuation for Yahoo's Alibaba stake. According to Yahoo's balance sheet they have about 16B in assets, but it is plainly evident that their remaining stake in Alibaba alone is worth more than that. Even if you grossly overestimate the taxes Yahoo could pay on the Alibaba stake, Yahoo is still trading at less that 2x book value at $40. Considering that it is almost unheard of for a profitable tech company to trade at a price to book ratio that low, Yahoo isn't expensive, it's a value proposition.
    Sep 19 12:49 PM | 1 Like Like |Link to Comment
  • Yahoo: On First Glance Cheap, On Second Glance Expensive [View article]
    Even if you grossly overestimate the taxes Yahoo could pay on the Alibaba stake, Yahoo is still trading at less that 2x book value at $40. Considering that it is almost unheard of for a profitable tech company to trade at a price to book ratio that low, Yahoo isn't expensive, it's a value proposition.
    Sep 19 12:43 PM | Likes Like |Link to Comment
  • Tesla Will Lead In Self-Driving Vehicles [View article]
    Yesterday at the shareholder's meeting: "So I think we are making some really good progress on the autopilot side, and I am confident that in less than a year you will be able to go from highway on ramp to highway exists without touching any controls." Seems to coincide nicely with Model X ramp up next spring. On ramp to exit ramp is a pretty huge step forward.
    Jun 4 04:31 PM | 4 Likes Like |Link to Comment
  • Is Tesla The New Qualcomm? [View article]
    Interesting article, nice to see a bear perspective fleshed out by more than simply saying TSLA is overvalued, you definitely bring up some valid points. One point that might be useful if you think the Qualcomm/Tesla comparison is worthwhile is to take a look at the price to book of Qualcomm over time and compare it to Teslas, I would venture a guess ( I haven't looked at it) that QCOM's p/b was quite high around 99', much higher than TSLA now, and I would also guess that TSLA's growth potential is much faster and robust, so that might be worth taking a look at and seeing how it adds to the comparison.
    May 13 11:22 AM | 1 Like Like |Link to Comment
  • Neuralstem's Cell Therapy Is Working, And This Is Just The Beginning [View article]
    Is there an estimate for when Phase 2 will be completed?
    May 7 10:25 PM | Likes Like |Link to Comment
  • Positive Signs From Neuralstem's Phase 2 ALS Trial [View article]
    Thanks, I hope they find a way to speed through phase II or publish interim data to the FDA, this therapy really ought to be in broader use by now.
    Apr 18 02:36 PM | Likes Like |Link to Comment
  • Positive Signs From Neuralstem's Phase 2 ALS Trial [View article]
    Have they ever mentioned when the Phase II is planned to conclude or if there will be an interim update?
    Apr 17 11:23 PM | Likes Like |Link to Comment
  • Time To Back Up The Truck On Cytomedix? [View article]
    That was a good report, glad to see them getting Autologel on the market and to medical providers. Seems like they have a full plate for now but is there any talk of applications outside of wound care like burns or cosmetic? Seems like it could serve as a useful supplement or even a replacement for a pretty wide swath of treatments.
    Apr 4 04:36 PM | Likes Like |Link to Comment
  • Why Seeking Alpha Embraces Pseudonymity [View article]
    P.S. When I wrote "Or often you get halfway through an article ..." I should have said every once in a while, not often, didn't mean to sound overly critical, just constructive.
    Mar 20 01:21 AM | 1 Like Like |Link to Comment
  • Why Seeking Alpha Embraces Pseudonymity [View article]
    Eli,
    Thanks for that well thought out policy explanation, the use of pseudonyms is tricky but hopefully most who do so do it for good reasons. Glad to know you guys are thinking about things like that. One other thing that concerns me with SA sometimes is that in some sense SA is a place where people come to be educated in finance, business, economics etc. A reader or contributor could be a seasoned hedge fund manager or a novice with almost zero investing experience. Both can probably have worthwhile contributions as long as they are clear about where they are coming from, but with the growth of SA, one of the things I've noticed is that more and more of the contributors aren't really qualified to be "educators" in those subjects in the sense that they often do not actually know the definitions of the terms or concepts that they are using, and yet they have a platform to "teach". Or often you get halfway through an article only to realize that the author doesn't actually understand what they are talking about in spite of their bio suggesting that they are experts. Moreover, I know of at least one pretty prolific contributor who has written over 20 articles about one company/industry and been wrong in pretty much every sense every time. Disagreement and contrarian ideas are important, but 20+ wrong articles in a row doesn't really seem like it should happen, it's a disservice if SA is incorrectly educating people for clicks. If SA wants to keep growing I'm not really sure there is an easy fix for the issue, it may just come down to quantity vs quality and of course being clear about their qualifications. But one thing I was thinking might help is to loosen the idea that every article has to be an actionable suggestion that is written authoritatively, that way someone who isn't qualified to write authoritatively but still wants to contribute and maybe start an insightful discussion can write an article without feeling like they have to misrepresent themselves and sound like a professional. Of course that doesn't solve the problem when well qualified authors write authoritatively and are just wrong. Anyway I'm sure that's stuff you already consider, just my 2c, hope it's constructive.
    Mar 20 12:47 AM | 1 Like Like |Link to Comment
  • Galena: Setting The Record Straight [View article]
    So maybe to steer the conversation towards what seems like the most relevant thing: how good is Neuvax? I've only loosely been following GALE, so maybe some of these questions are already answered, but is it looking like Neuvax is best suited as a treatment, as a vaccine? What kind of efficacy is it looking like? Does it offer something better than the current standard?
    Mar 18 06:56 PM | 1 Like Like |Link to Comment
  • Tesla's Deflationary Creative Destruction Has Not Even Begun [View article]
    +1 Tesla might be overvalued but that doesn't mean it's a great short right now. The sooner you exit a bad trade, the sooner you can enter a good one.
    Mar 18 05:55 PM | 2 Likes Like |Link to Comment
  • Tesla's Deflationary Creative Destruction Has Not Even Begun [View article]
    Seems like a lot of the confusion over the importance of regional deliveries/orders could be easily remedied by using some common sense and listening to the last conference call. Tesla is a sniper rifle right now, they are just targeting strategic regional markets one by one, at the expense of other less priority markets. The market is expanding and Tesla just doesn't have enough bullets to hit every target at the same time...a good problem to have in business.

    George, interesting+well balanced article. On the growth side it makes you wonder how the battery industry will look in ten years.
    Mar 18 05:44 PM | 2 Likes Like |Link to Comment
COMMENTS STATS
513 Comments
439 Likes